Inqovi (decitabine / cedazuridine) is an anticancer medication that’s used for treating a group of blood problems called myelodysplastic syndromes (MDS) in adults. The combination tablet contains decitabine, a type of chemotherapy called a hypomethylating agent, and cedazuridine, a cytidine deaminase inhibitor that helps the chemotherapy work better. Inqovi (decitabine / cedazuridine) is taken by mouth once daily for the first 5 days of every 28-day treatment cycle. It can cause side effects like tiredness, mouth sores, and low blood cell counts.
In people with MDS, immature blood cells don’t develop properly into normal, healthy blood cells (such as white or red blood cells). Instead, the blood cells continue to grow as immature cells. As a result, people with MDS have a lot of immature blood cells that don’t work correctly and very few fully-developed, healthy blood cells.
Inqovi (decitabine / cedazuridine) is a combination medication containing two active ingredients that work together to treat MDS.
The following side effects may get better over time as your body gets used to the medication. Let your healthcare provider know immediately if you continue to experience these symptoms or if they worsen over time.
Note: Side effects listed were reported from people after only the first treatment cycle of Inqovi (decitabine / cedazuridine).
Contact your healthcare provider immediately if you experience any of the following.
Side effects that you should report to your care team as soon as possible:
Side effects that usually do not require medical attention (report to your care team if they continue or are bothersome):
Yes. Inqovi is a combination medication that contains decitabine, which is typically categorized as chemotherapy. The term chemotherapy refers to medications that work to kill fast-growing cells. At high doses, decitabine can kill cancer cells. But for treating myelodysplastic syndromes (MDS), decitabine is given at lower doses to specifically help the body recognize blood cells that aren’t growing correctly. This allows the body to either destroy unhealthy blood cells or fix them so that they can turn into healthy blood cells. The other active ingredient in this combination medication, cedazuridine, helps decitabine stick around longer in the body to treat MDS.
Inqovi (decitabine / cedazuridine) most commonly causes you to have a low blood cell count. It can make your white blood cell count drop. This weakens your immune system, raises your risk of getting sick, and makes it harder for you to recover from infections. Inqovi (decitabine / cedazuridine) can also make your red blood cell count lower, which can lead to anemia and make you feel tired. What’s more, you can have low platelet levels, which might put you at risk for bleeding. Your oncologist will check your blood cell counts often while you’re taking Inqovi (decitabine / cedazuridine). Contact your care team if you have any unexpected bruising, bleeding, tiredness, or any signs of infection.
Although it’s possible, most people who take Inqovi (decitabine / cedazuridine) don’t lose their hair. Some things you can do to help if you do notice any hair loss or hair thinning include using a soft-bristled brush, only washing your hair when necessary, and using mild shampoos. You might also want to talk to your oncology care team because there can be other causes of hair loss.
Yes. Inqovi (decitabine / cedazuridine) can cause nausea, but it’s usually not severe. Your oncologist will prescribe medications for you to take before each time you take Inqovi (decitabine / cedazuridine) to help prevent or ease any nausea. Speak with your oncologist if you have severe nausea that doesn’t get better with medications.
It can take up to a day for most of Inqovi (decitabine / cedazuridine) to leave your system after a single dose. This time frame is based on the medication’s half-life, which is the amount of time it takes the body to get rid of half the amount of medication in the system. Ask your oncologist if you have concerns about how long Inqovi (decitabine / cedazuridine) stays in your system.
If you’ve missed a dose of Inqovi (decitabine / cedazuridine) and it’s more than 12 hours until your next dose, take the medication as soon as possible and continue with your treatment schedule. If there are less than 12 hours until your next dose, skip the missed dose and wait until the next day to take the medication at your usual time at the usual dose (don’t take extra tablets to make up for missed doses). For each missed dose that you skipped, add a day that you’ll take Inqovi (decitabine / cedazuridine) in the treatment cycle so that you end up taking 5 doses of the medication. Ask your oncologist or pharmacist if you’re not sure what to do if you forget to take the medication.
If you vomit right after you take your Inqovi (decitabine / cedazuridine) tablet, don’t take an extra tablet to make it up. Wait until the next time you typically take the medication to take your usual dose.
Avoid breastfeeding while you’re taking Inqovi (decitabine / cedazuridine) and for 2 weeks after your last dose. We don’t know whether the medication is found in breast milk, whether it affects your milk supply, and whether it affects breastfed babies. But there’s a possible risk of harm to a baby. Speak with your care team about alternative ways of feeding your baby, such as baby formula.
Inqovi (decitabine / cedazuridine) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
Inqovi (decitabine / cedazuridine) commonly causes low blood cell counts. This can be serious and life-threatening. Having low levels of red blood cells can lead to problems like feeling more tired and anemia. In addition, having low platelets can put you at risk for easy bleeding. And having low levels of white blood cells can put you at risk for serious, dangerous infections.
Low blood cell counts are more common during the first or second cycles of Inqovi (decitabine / cedazuridine). In particular, you might be more likely to develop low white blood cell counts if you’re older than 65 or if you’ve had chemotherapy or radiation before.
You’ll need to get a blood test done to check your blood cell counts before every treatment cycle with Inqovi (decitabine / cedazuridine). If your counts are too low, your oncologist might make adjustments to your treatment to give your body time to make new blood cells. This could mean taking the cancer medication for fewer days than usual per cycle or pausing treatment. Your oncologist might also add medications to your treatment plan to boost your white blood cell count or prescribe antibiotics to prevent infections.
Based on studies and the way Inqovi (decitabine / cedazuridine) works, the medication could cause harm to an unborn baby if it’s taken during pregnancy.
If you’re able to become pregnant, you should use effective birth control while you’re taking Inqovi (decitabine / cedazuridine) and for 6 months after your last dose. If you’re a male who’s sexually active with a partner who can become pregnant, use birth control like condoms if you have sex while you’re taking this cancer medication and during the 3 months after your last dose. Contact your oncology care team right away if you or your partner becomes pregnant while you’re taking Inqovi (decitabine / cedazuridine).
| Dosage | Quantity | Price as low as | Price per unit |
|---|---|---|---|
| 5 tablets of 35mg/100mg | 1 carton | $8,548.08 | $8,548.08 |
Each tablet contains 35 mg of decitabine and 100 mg of cedazuridine.
The usual dose is 1 tablet by mouth once a day on days 1 through 5 of each 28-day treatment cycle.